Live Trading News
Vertex Pharmaceuticals Target Price $300 - Live Trading News
Vertex Pharmaceuticals Target Price $300 Headline News
Search for a Stock
Vertex Pharmaceuticals, Inc. VRTX: $225.55
50 Northern Ave, Boston, Massachusetts, US. | Sector: Manufacturing | Exchange: NASDAQ/NGS (GLOBAL SELECT MARKET) | Web: https://www.vrtx.com/
An Average Investor typically allocates 6.19% of their total portfolio to Vertex Pharmaceuticals, Inc..
Neutral
Investor Sentiment
$2.640
Current EPS
8.21%
Return on Equity
Neutral
Technical Analysis
Bullish
News Sentiment
$10.22
Trailing 12 Month EPS
Bought Shares
Insiders Activity of Last 6 Months
Latest News About Vertex Pharmaceuticals, Inc.
STAT News
STAT+: Vertex Pharma taking more aggressive M&A stance, flush with cash from cystic fibrosis drugs
Vertex Pharmaceuticals is looking to acquire “mid- and late-stage assets” to bolster its current research pipeline, CEO Reshma Kewalramani said.
CompanyNewsHQ
Vertex to Present at the J.P. Morgan Healthcare Conference on January 11 | Vertex Pharmaceuticals (Vertex Pharmaceuticals) | CompanyNewsHQ
(Vertex Pharmaceuticals) BOSTON--(BUSINESS WIRE)--Jan. 7, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the J.P. Morgan
Business Wire
Vertex to Present at the J.P. Morgan Healthcare Conference on January 11
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the J.P. Morgan Healthcare Conference on Monday, January 11, 2021 at 9:10 a.
Investing.com
RBC Capital Stick to Their Buy Rating for Vertex Pharmaceuticals
RBC Capital Stick to Their Buy Rating for Vertex Pharmaceuticals
Business Wire
Vertex Announces European Commission Approval for SYMKEVI® (tezacaftor/ivacaftor) With KALYDECO® (ivacaftor) for Eligible Children With Cystic Fibrosis Ages 6-11 Years
LONDON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the European Commission has granted approval of the label extension for SYMKEVI® (tezacaftor/ivacaftor)
Benzinga
Odds Of Vertex's Pipeline Success Aren't Dismal As Some Fear, Bernstein Says
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) shares have come under selling pressure recently, given investor concern regarding diversity in the pipeline for this cystic fibrosis-focused biopha
Transcript Daily
Vertex Pharmaceuticals (NASDAQ:VRTX) Earns Outperform Rating from Analysts at Sanford C. Bernstein
Sanford C. Bernstein started coverage on shares of Vertex Pharmaceuticals (NASDAQ:VRTX) in a research report issued on Friday, The Fly reports. The brokerage set an “outperform” rating and a $275.00 p
CBC News
Cystic fibrosis drug Trikafta could change lives - if Health Canada approves it
After a year of hesitation in the face of pending cost control guidelines, Vertex Pharmaceuticals has submitted Trikafta to Health Canada for approval - now the hard work begins, writes Jeremie Saunde
CompanyNewsHQ
Vertex Recommends Rejection of ‘Mini-Tender’ Offer From TRC Capital Investment Corporation | Vertex Pharmaceuticals (Vertex Pharmaceuticals) | CompanyNewsHQ
(Vertex Pharmaceuticals) BOSTON--(BUSINESS WIRE)--Nov. 13, 2020-- Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) today announced that it has been notified of an unsolicited